Competition from Alternative Cancer Treatments and Advances in Biotechnology
First written in FY2017. 1 of 2 entries say "Materialised", first in FY2018-Q3. Latest entry: FY2018-Q3.
Medinet moved to the "Worse" side of this theme in 2018, 4 years before the typical company in this theme (2022).
The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.
2 other companies' latest entry also says "Materialised".
- FY2018-Q3MaterialisedAnnual report
「Revenue from physician-directed immune-cell processing for cancer, which had previously been our core business, fell sharply owing to changes in the cancer-treatment environment, including the growing use of immune checkpoint inhibitors.」
The competitive risk associated with the wider adoption of alternative cancer treatments and biotechnology is described as a sharp decline in revenue resulting from the growing use of immune checkpoint inhibitors and other factors. - FY2017First statedAnnual report
「If highly effective pharmaceuticals are developed independently of their use in combination with immune cell therapy, this could affect the Group’s performance.」
The Company discloses the development of immune checkpoint inhibitors and other alternatives to immune cell therapy as competitive risks.